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Abstract 
In the past, malaria control efforts in sub-Saharan Africa have relied on a combination of 
vector control and effective treatment using chloroquine.  With increasing resistance to 
chloroquine, attention has now turned to alternative treatment strategies to replace this failing 
drug.  Although there are strong theoretical arguments in favor of switching to more expensive 
artemisinin-based combination treatments (ACTs), the validity of these arguments in the face of 
financial constraints has not been previously analyzed. In this paper, we use a bioeconomic 
model of malaria transmission and evolution of drug resistance to examine questions of optimal 
treatment strategy and coverage when drug resistance places an additional constraint on choices 
available to the policymaker. Our main finding is that introducing ACTs sooner is more 
economically efficient if the planner had a relatively longer time horizon. However, for shorter 
planning horizons, delaying the introduction of ACTs is preferable. 
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ACT Now or Later: The Economics of Malaria Resistance 
Ramanan Laxminarayan1 
1. Introduction 
Parasite resistance to chloroquine (CQ) has risen steadily in recent years in many 
malaria-endemic countries in sub-Saharan Africa, with consequent increases in malaria 
morbidity and mortality (Trape 2001).  The imminent loss of this important drug in the 
fight against malaria has hampered malaria control efforts and placed greater 
responsibility on policymakers to rapidly change their guidelines on antimalarial 
treatments, keeping in mind the possibility that alternatives to CQ also could be rendered 
obsolete by drug resistance.  Given the limitations on financial resources in most malaria-
endemic countries, there has been considerable difficulty in deciding on an alternative 
treatment that is both affordable as well as sound from a long-term perspective. 
Artemisinin-based combination treatments (ACTs) hold considerable promise of both 
increased efficacy and retardation in the rate of development of parasite resistance. 
Although the theoretical basis underlying the epidemiological advantages of artemisinin-
containing combinations in the treatment of malaria has been studied (Curtis et al. 1986; 
Hastings et al. 2000; White 1999; White 1998), little attention has been paid to the 
economic desirability of using ACTs.  The focus of this paper is on the economic 
evaluation of alternatives to the current chloroquine guidelines, and the implications for 
the allocation of scarce financial resources for malaria treatment, when future resistance 
is a consideration. 
In response to growing resistance to CQ, many countries have considered changing 
their official guidelines for first-line treatment to either sulfadoxine-pyrimethamine (SP) 
                                                 
1 Fellow, Resources for the Future. I thank Ellis McKenzie, Rustom Antia, Ian Hastings and Nick White for 
useful advice on the epidemiological model, and Ken Arrow, Dean Jamison, Hellen Gelband and 
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or ACTs.  SP offers distinct advantages over ACTs in that it costs roughly a tenth that of 
ACTs per treatment dose, is administered as a single treatment, and is approved for use in 
children and pregnant women.2 An important drawback with switching to SP, however, is 
that resistance to the drug is expected to increase with widespread use and may leave 
policymakers with a similar situation of growing malaria morbidity and mortality a few 
years from now (Winstanley 2000).  An alternative strategy would be to switch to ACTs 
immediately.  ACTs offer the advantage of delaying resistance for a much longer time 
period than SP while offering faster cure rates. However, there is some concern about 
whether ACTs would actually work to delay resistance in sub-Saharan Africa, where 
there is poor adherence to treatments and underdosing, among other concerns (Bloland et 
al. 2000).  Furthermore, there is uncertainty about the benefits of ACTs because of the 
potential for monotherapy—use of only one of the drugs rather than the combination 
prescribed for therapy. 
In this paper, we develop a mathematical, bioeconomic model of malaria 
transmission, immunity, and drug resistance.  The model is then applied to addressing 
two specific questions.  First, we compare the economic consequences of two strategies, 
the first of which involves replacing CQ with ACTs, and the second of which involves 
replacing CQ with SP and waiting for resistance to develop before introducing ACTs.  
The second question addressed in this paper pertains to the optimal level of coverage 
using ACTs. Here one is faced with the constraint that while increasing access to an 
effective antimalarial in any given region or location both lowers morbidity and saves 
lives, it involves higher costs and an increasing likelihood that resistance will develop to 
                                                 
2 There is substantial disagreement over the cost of ACTs. Current estimates vary between $1.00 per adult 
dose (Médecins Sans Frontières) and $2.50 for artemether-lumafantrine at the price negotiated by the 
World Health Organization for developing countries.  It is likely that with widespread adoption of new 
ACTs, the price will drop significantly and the lower bound estimate of $1.00 would be a reasonable 
approximation of the long-run marginal cost of these treatments.  The current price for SP is roughly $0.12 
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the drug being used3. Furthermore, policymakers may have to decide whether to devote 
all their resources to increasing treatment coverage in a few regions or to distribute these 
resources over a larger number of regions. 
2. Mathematical Model 
The use of antimalarials involves costs and benefits that occur at different points in 
time.  On the one hand, using effective antimalarials in the present benefits society by 
lowering the current economic burden of malaria morbidity.  On the other hand, 
expanding the use of antimalarials, while increasing the cost of treatments, potentially 
increases the likelihood that resistance will evolve, which in turn could lead to greater 
morbidity in the future.  Converting present and future morbidities into economic metrics 
permits a consistent comparison of different strategies for antimalarial use over the 
policymaker's planning horizon. 
The policymaker's objective is to inter-temporally minimize the sum of discounted 
present value of the costs of infection and the costs of treatment.  This objective is 
constrained by the biology of the disease as reflected by the dynamics of malaria 
transmission and the evolution of drug resistance.  Disease dynamics are modeled using a 
compartmental model where individuals move between healthy (susceptible), infected, 
and immune classes.  Although factors such as age structure, degree of parasitemia, 
latency, and genetic variability play an important role in malaria dynamics, the model 
presented is abstracted from these secondary considerations to focus sharply on the role 
of treatment in malaria transmission and the evolution of resistance and immunity. 
Malaria transmission is assumed to be year-round and stable.  A constant population size 
is assumed with no net migration or change in age structure.  Superinfections are ruled 
                                                 
3 Although the use of ACTs is likely to induce resistance than the use of drugs in monotherapy, the 
probability of resistance arising to ACTs is greater for higher levels of treatment coverage. If, however, 
increasing ACT coverage implies less use of the partner drug in monotherapy then this could lower the 
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out, although this may make a quantitative difference in terms of increasing infection 
rates (Anderson et al. 1991). 
Biology 
We follow the basic mathematical model of malaria described in Koella (1991) and 
earlier papers (Aron 1988a; Aron 1988b), modified to incorporate the evolution of 
resistance (see Figure 1 for schematic).4  As in previous literature in this area, we assume 
that the mosquito dynamics operate on a much faster time-scale than the human 
dynamics, so that the mosquito population can be considered to be at equilibrium with 
respect to changes in the human population, and its dynamics can be collapsed into the 
inoculation rate (Koella 1991).  
Resistance arises in this model in the following way.  Initially, there is a small 
proportion of infecteds who carry a resistant strain.  This initial frequency of resistance is 
believed to be in the order of magnitude of 
12 10
− in the case of artemisinin-based 
combinations, and 
3 10
−  for treatment with SP.  Over time, the treatment selection 
pressure leads to a greater prevalence of infecteds who carry the resistant strain relative to 
those that carry a sensitive strain.  Working in the opposite direction is the fitness cost of 
resistance.  Resistant strains face an evolutionary disadvantage, which is manifested in a 
higher patient recovery rate from resistant infections, as described in the model below.  


























 (see Appendix A for derivation) for wild-type and resistant 
strains, respectively, where a is the biting rate (number of bites per female mosquito per 
night),  1 b  is the infectiousness of humans to mosquitoes,  2 b  is the susceptibility of 
                                                 
4 Since this paper was completed, a new paper published by Koella and Antia (2003) that incorporates 
resistance into a model of malaria transmission has been brought to my attention. Their model differs only 
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mosquitoes to humans, m is the mosquito density (number of mosquitoes per human), 
τ is the incubation period of parasites in the mosquito, and µ is the mortality of 
mosquitoes.  y  denotes the proportion of infected individuals in the human population 
(see equations below),  w y  is the fraction of infected patients with a susceptible strain, 
and  r y  carry a resistant strain ( y y y r w = + ).  Let the proportions of susceptibles and 
immunes be denoted by x and z  so that  1 = + + + z y y x r w .  The differential equations 
that describe changes in the classes of susceptibles, infecteds (wild-type or sensitive 
strain), infecteds (resistant strain), and immunes are, 
(1) () wr w x xx h h zfy δ δγ α =− − + + +   
(2) () ww w w w yh x yf y θ δα =−+ −   
(3) () rr r r yh x y θδ =−+   
(4) () ww rr zy y z θ θγ δ =+ − +   
Susceptible (or healthy) individuals become infected with a sensitive parasite at rate 
w h , the inoculation rate for sensitives, and with a resistant parasite at rate  r h , defined 
earlier. 56   Individuals with a wild-type strain recover at rate  w θ  to enter the immune 
class, while individuals with a resistant strain recover at rate  r θ . The spontaneous rate of 
recovery from the resistant infection is assumed to be greater than that for sensitive 
infections; hence,  w r θ θ ≥ .  The difference between these rates represents the treatment 
                                                 
5 Interventions such as impregnated bednet use will likely reduce this transmission coefficient.  Although 
the use of ACT is expected to reduce gametocyte carriage and hence parasite transmissions, we shall 
assume that ACT reduces transmission primarily by curing patients more rapidly. 
6 One strand of the mathematical epidemiology literature on malaria resistance focuses on the relative 
importance of transmission rates on evolution of drug resistance (Mackinnon 1997; Mackinnon and 
Hastings 1998).  According to one camp, high transmission results in higher recombination breakdown if 
resistance is coded by more than one locus.  The other camp holds that drug selection pressure is the more 
powerful force; therefore, higher transmission rates lead to increased resistance.  The model implicitly 
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  6
fitness cost of resistance.7 Immunes become susceptible again at rate γ . The period for 
latency of infection in humans is assumed to be zero. α  represents the rate of recovery of 
patients infected with a wild-type infection who receive treatment. The inverse of this 
parameter, therefore, represents the mean duration of illness for a treated individual with 
a wild-type infection. δ  is the population death (and birth) rate and is unrelated to 
disease status, m.  Transmission fitness cost of resistance is assumed to be negligible.8 
Births equal deaths, so the population size remains unchanged.  
f  is the fraction of the infected population that receives treatment.  Infected 
individuals who are treated successfully (because they carry a sensitive parasite) return to 
the susceptible state.  There is some evidence that the benefit of effective treatment is 
accompanied by a loss of immunity (Cornille-Brogger et al. 1978; Pringle et al. 1966). 
Treatment, therefore, retards expansion of the immune class. The use of ACTs or some 
similar effective treatment strategy does not alter transmission intensity in this model, but 
reduces the number of parasites in circulation by reducing the duration of illness. 











It is customary to describe the basic reproductive number as the number of secondary 
cases of malaria arising from a single case in an otherwise uninfected population 
(Macdonald 1957).  In our model, the reproductive number depends on whether this case 
is of a wild-type strain or a resistance strain.  The reproductive number of susceptible and 
resistant parasites is given by: 
                                                 
7 For a discussion of the fitness cost of resistance, see Koella 1998. 
8 It is possible that resistant parasites are less likely to be transmitted from humans to mosquitoes and back 
and this places them at an evolutionary disadvantage with respect to sensitive parasites.  It is also possible 
that resistant parasites are more likely to be transmitted, which gives them a transmission fitness advantage 






























 respectively (see Appendix A for 
derivation). 










.  Increasing treatment 
coverage increases this ratio.  At  0.5 f = , this ratio is equal to 3 for the baseline 
parameter values used in our model.  In other words, if 50% of the infected population 
were to receive treatment, a resistant strain introduced in a population comprised entirely 
of susceptibles is three times as likely to generate a secondary infection as a wild-type 
strain. The critical coverage at which the increase in resistance due to selection pressure 
placed on sensitive strains is exactly equal to the decrease in resistance because of the 





= , which is roughly 0.12 for the 
parameter values used in our model (see Appendix C for derivation).  At this steady state 
level of coverage, the level of resistance to the drug remains unchanged.  Higher levels of 
coverage are associated with increasing resistance, while lower levels of coverage are 
associated with decreasing resistance.  
Economics 
A number of studies have examined the direct and indirect costs of an episode of 
malaria (Chima et al. 2003; Ettling et al. 1994; Ettling et al. 1991a; Ettling et al. 1991b; 
Sauerborn et al. 1991).  However, these costs tend to be highly context- and location-
specific, with limited applicability to other settings (Gomes 1993).  A range of cost 
estimates for morbidity and treatment are drawn from the existing literature to allow a 
sensitivity analysis based on variations in the cost parameters. 
Estimates of lost work time range from one to five days per episode. In general, 
indirect costs associated with lost productive labor time account for a relatively large 
fraction of the overall costs of malaria. For instance, a study that surveyed 1,614 
households in rural Ghana found that the average direct cost of treating malaria, which Resources for the Future                                                                                        Laxminarayan   
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included the cost of drugs, consultation, laboratory service, and transportation, 
constituted roughly 20% of the cost of treatment.  Indirect costs that measured the 
opportunity cost of travel, time, waiting, and loss of productive time made up the 
remaining 80% (Asenso-Okyere et al. 1997). Another study that compared malaria-
related costs in four sites in Africa (in Rwanda, Burkina Faso, Chad, and Congo) found 
that, on average, a case of malaria cost $1.83 (1987 $) in direct costs (treatment 
expenditure and control) and $9.84 in indirect costs (morbidity, mortality, and economic 
losses) (Shepard et al. 1991). In all sites, the indirect costs were much higher than the 
direct costs and typically accounted for roughly 90% of total costs (excluding quality-of-
life costs).  These studies indicate that the cost of drug treatment may only be a small 
percentage of the overall costs of treating malaria. 
For the purpose of our simulations, we assume a morbidity cost of $1.50 per infected 
patient per day for the baseline analysis, based on the above cost estimates and average 
duration of illness.  In the base case, the cost of a dose of SP was assumed to be $0.12 
and the cost of ACTs was assumed to be $1.00.9 Non-drug treatment costs were assumed 
to be zero in the baseline analysis.  Higher non-drug treatment costs were likely to make 
differences in the cost of the drug itself less critical in the choice of strategy.10  Including 
the cost of treatment favors the strategy of introducing ACTs immediately since the cost 
of the drug may not add substantially in percentage terms to the costs associated with 
malaria.  Finally, all costs were discounted at a constant, annual rate of 3%. 
                                                 
9 In a recent paper, Snow and colleagues report a $1.20 cost for an adult dose of AS+SP (sulphadoxine, 25 
mg per kg of body weight over one day; pyrimethamine, 12.5 mg per kg of body weight over one day; 
ART, 4 mg per kg of body weight over three days); $1.30 for an adult dose of AS+Amodiaquine (AQ, 25 
mg per kg of body weight over three days; ART, 4 mg per kg of body weight over three days); and $2.40 
for an adult dose of Coartem© (lumefantrine, 48 mg per kg of body weight over three days; artemether, 8 
mg per kg of body weight over three days) (Snow et al. forthcoming). 
10 If non-drug treatment costs were $4 for instance, then the cost of ACT treatment is only roughly 20% 
higher than that of SP treatment.  With zero non-drug treatment costs, the relative cost of ACT treatment is 
higher.  One reason for including only the drug costs was to examine the problem from the perspective of a 
Ministry of Health that is concerned about the impact on its drug budget of different treatment strategies. Resources for the Future                                                                                        Laxminarayan   
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Analysis 
The initial conditions for the model were such that the disease was in steady state 
and there was no drug in circulation.  A proportion of newly infected cases are treated 
immediately.  Present discounted cost of treatment and infection for different levels of 
coverage were computed and compared for two treatment strategies.  In strategy A, ACTs 
were introduced immediately and resistance was allowed to evolve as an increasing 
function of treatment coverage.  In strategy B, SP was introduced at time 0 and resistance 
was allowed to evolve to 20%, at which point the treatment was switched to ACTs.  The 
resistance switch point was selected arbitrarily and one could well make a case for it 
being higher or lower. The switch point was varied to 40% in the sensitivity analysis. 
Computations were made for a base population of 1 million. In order to focus on the 
cost of ACTs and the optimal levels of coverage based on treatment and infection costs, 
we made the simplifying assumption that those who do not receive ACTs take 
chloroquine or some other drug that does not compromise the long-term efficacy of the 
combination treatment.  If this assumption were to be relaxed, we find that we may be 
worse off with very low levels of ACTs coverage (relative to coverage with monotherapy 
with either drug in combination) than with no ACT use at all.  Furthermore, the success 
of ACTs would depend largely on reducing use of the artemisinin derivative's partner 
drug in monotherapy.  Malaria-specific mortality was assumed to be zero, although 
introducing an appropriate case-fatality rate did not alter any of the results qualitatively. 
Model parameters are summarized in Table 1 and justification is provided in 
Appendix D.  In addition, we have conducted extensive sensitivity analyses around these 
point estimates, some of which are described in the following section. 
3. Results 
Since the parameter values used in the simulations were intended to broadly 
represent the situation in sub-Saharan Africa and are not precisely applicable to any 
single context, it is probably more useful to focus on the qualitative results and orders of 
magnitude indicated rather than on the numbers themselves. Figure 2 plots the infection Resources for the Future                                                                                        Laxminarayan   
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rates and resistance for three levels of coverage (20%, 40%, and 60%) over three time 
horizons; 5, 10, and 20 years, to represent the short, medium, and long term for different 
runs of Strategy A.  Infection rates initially decline in response to the introduction of the 
effective drug to replace chloroquine.  However, the decrease in infection rates 
attributable to the effective drug is partly offset by increasing levels of infection because 
of declining immunity. Infection levels further increase in response to increasing 
resistance.  The increase in infection levels is most rapid for higher rates of treatment 
coverage, which also achieve greater reductions in infection levels in the short term 
because more patients are being treated.  In the longer term, infection levels decline with 
the increase of immunity to the parasite.   
The increase of parasite resistance follows the familiar logistic function.  The third 
plot describes the present discounted cost of treatment and infection for three different 
levels of coverage with an effective treatment such as combination treatment.  Higher 
levels of treatment coverage shifted the cumulative discounted cost curve downwards. 
Figure 3 plots the present discounted value of treatment and infection costs for 
Strategy A under the base case parameter values over three time horizons—5, 10, and 20 
years—to represent the short, medium, and long term.  Costs of infection declined for 
increasing levels of coverage, but at a declining rate.  Treatment costs increased linearly 
with treatment coverage.  Even at high levels of coverage, treatment costs represent only 
a small proportion (roughly 5%) of the economic costs associated with malaria morbidity. 
The same graph is repeated for Strategy B, where SP was introduced to replace CQ, 
in Figure 4.  Here too, the costs of malaria morbidity were declining with increasing 
treatment coverage even after resistance related impacts on future morbidity were taken 
into consideration.  Figure 5 displays the difference in costs between strategies A and B.  
A positive value implies that Strategy B is more costly than strategy A.  Strategy B was 
preferred at both very low levels of coverage and high levels of coverage, but strategy A 
was preferred for coverage fractions ranging from 0.2 to 0.8 for a 20-year policymaking 
horizon. Broadly speaking, strategy B was the preferred option for a time horizon of five 
years, while strategy A was preferred if the policymaker's planning horizon extended to Resources for the Future                                                                                        Laxminarayan   
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10 or 15 years.  For a 40% level of treatment coverage, strategy A resulted in roughly $6 
million less in present discounted costs for the 10- and 20-year time horizons, while 
strategy B resulted in roughly $0.8 million less in present discounted costs over the five-
year horizon. 
When the cost of ACTs per treatment dose was increased from $1 to $2 in a 
sensitivity analysis, the cost of strategy A increased to a greater extent for all levels of 
treatment coverage (Figure 6).  However, the impact on overall cost differences between 
the two strategies remained unchanged. When the level of resistance at which a switch 
from SP to ACT was made in strategy B was changed from 20% in the base case to 60%, 
the relative advantage of strategy A declined for coverage below 0.5 for longer treatment 
horizons, but increased for coverage above 0.5 (Figure 7).  In a third sensitivity analysis, 
the discount rate was increased to 6% from the base case value of 3% (Figure 8).  This 
resulted in an improvement from the base case for shorter time horizons.  However, for 
longer time horizons, the cost advantage of strategy A was smaller relative to the base 
case.  Finally, the value of  0 R  was increased from 100 in the base case to 300 to capture 
settings of more intensive transmission (Figure 9).  This variation did not make a 
significant difference to the relative costs of strategies A and B from the base case. 
4. Discussion 
Artemisinin-based combination therapies (ACTs) that combine an artemisinin 
derivative with another antimalarial such as piperaquine or amodiaquine promise both 
increased efficacy and a reduction in the rate of development of resistance. Additionally, 
ACTs may help reduce malaria transmission, which in low transmission settings would 
reduce the incidence of malaria.  The current policy debate centers around whether 
malaria-endemic countries that face high disease burdens, due in part to increasing 
chloroquine resistance, should switch to ACTs, which are much more expensive than 
current drugs.  If these countries were to switch to SP as an interim measure, this would 
delay the higher treatment cost of ACTs.  The downside of the interim measure, however, 
is that resistance to SP is expected to rise in a few years, leading to increased morbidity 
and mortality.   Resources for the Future                                                                                        Laxminarayan   
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Our analysis shows that total discounted costs of infection decrease with increasing 
levels of coverage with either strategy.  This is attributable to faster cure rates, lower 
morbidity, and consequently to fewer secondary infections.  Further, discounted costs of 
infections decline more rapidly with treatment coverage for low levels of coverage.  After 
reaching a roughly 50% level of coverage, the decline in costs is no longer as dramatic, 
primarily because the increased risk of resistance developing in an area through higher 
coverage weigh against the benefits of treating more patients.  
We find that switching to SP first may be preferable at both very low and very high 
levels of treatment coverage.  At very low levels of treatment coverage and low selection 
pressure, resistance to SP is not a problem and so the least expensive drug is preferred.  
At high levels of treatment coverage, resistance evolves so rapidly regardless of which 
strategy is followed that the faster acquisition of immunity with a less effective drug 
plays a critical role in determining the superior strategy.  We find that for shorter time 
horizons, it may be economically desirable to switch to SP first to delay the costs of 
ACTs.   
If one were only interested in the short term, using the less expensive drug makes 
better economic sense since the costs of resistance-related morbidity do not enter the 
policymaker's set of considerations.  However, for longer planning horizons, a direct 
switch to ACTs may be desirable given the costs of higher morbidity associated with 
increasing resistance to SP.  With higher intensity of disease transmission, the benefit of 
switching to ACTs directly is diminished because of greater immunity associated with 
higher transmission, and hence a lower risk of resistance developing to SP monotherapy.  
Resistance to SP would be expected to take longer to develop and, therefore, the benefits 
of switching to SP first increase.   
Altering the cutoff level of SP resistance for the change in strategy B from 20% to 
60% does not change the difference in costs between the two strategies significantly. 
Increasing the discount rate places more weight on current costs and benefits compared to 
those that occur in the future.  This reduces the value of introducing ACTs since future Resources for the Future                                                                                        Laxminarayan   
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resistance-related morbidity costs play a smaller role in the policy decision, making it 
more desirable to introduce the cheaper drug (SP) initially. 
If countries could easily switch between drugs, it would make sense to introduce the 
cheaper drug (SP) first, and then move to ACTs before resistance to SP has had much 
impact on malaria morbidity.  However, this is not likely to happen for two reasons.  
First, malaria-endemic countries have shown great reluctance to modify their malaria 
treatment policies proactively in response to impending resistance-related morbidity.  The 
fact that CQ is being used even with high treatment failure rates when an alternative drug 
(SP) is available is emblematic of policy failures in health decision-making.  Second, the 
costs of each change in treatment policy may be large.  These policy change costs are 
associated with retraining health workers, printing material that explains new dosing 
regimes, restocking new drugs, and so forth, and can be significant in the short term.  In 
the case of a switch to SP, these policy change costs would have to be amortized over a 
much shorter life of the drug than in the case of a switch to ACTs.  Our analysis, which 
does not incorporate these policy change costs, therefore errs on the side of being 
conservative with regard to cost advantages of a direct switch to ACTs. 
There are other considerations that play an important role in the selection of the most 
appropriate antimalarial treatment strategy.  First, an important parameter that determines 
the evolution of resistance to ACTs is the starting frequency of resistance, not just to 
artemisinin, but also to the partner drug in the combination.  With the widespread 
availability of all antimalarials from private drug sellers in Africa, it may be difficult to 
control the emergence of resistance to the companion drug, which in turn would expedite 
the emergence of resistance to the combination.  Our model shows that the economic 
advantages of introducing ACTs immediately are generally lower for higher starting 
frequencies of resistance to either drug in the combination, although this result depends 
on the impact of effective treatment on retarding the acquisition of immunity.  Second, 
SP involves a one-day treatment dose, which is much easier to comply with than the five-
day treatment of ACTs.  To the extent that reduced compliance, which is more likely in 
the case of ACTs, will significantly expedite the evolution of resistance, our analysis errs 
on the side of overstating the economic advantages of immediate introduction of ACTs. Resources for the Future                                                                                        Laxminarayan   
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Our analysis also indicates that there may be decreasing returns to treatment 
coverage. In other words, expanding treatment coverage from 10 to 20% may yield much 
greater benefit than expanding coverage from 60 to 70%. Given the tight constraints 
placed on malaria treatment resources in sub-Saharan Africa, it may be economically 
efficient to maximize availability of antimalarials in all areas rather than focusing 
resources on just a few areas. However, other factors such as scale economies in 
treatments may also play a role and work in the opposite direction.   
In spite of evidence of significant societal benefits of ACTs, policymakers are likely 
to be deterred by the immediate cost of ACTs and the burden that adopting a more 
expensive drug would place on their already overextended health budgets.  However, the 
real choice is not about whether or not to use ACTs, but whether to introduce them now, 
or to delay their introduction for a few years while SP could be used.  This situation could 
change with the introduction of new and improved antimalarials, but the prognosis for 
this happening is bleak.  Ultimately, it is the planner's time horizon that will play an 
important role in naming a successor to chloroquine.Resources for the Future                                                                                        Laxminarayan   
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Appendix A: Derivation of inoculation coefficient 
The derivation of the inoculation coefficient is provided in Koella (1991).  The 
inoculation coefficient is given by: 
(A.1) 2 hm a b w =  
where m, a, and  2 b are as defined earlier and wis the proportion of mosquitoes with 
sporozoites in their salivary glands.  The population of mosquitoes comprises w, a 
proportion, v, of mosquitoes that are infected but have not yet developed sporozoites, 
and uninfected proportion given by 1 vw − − .  The equations of motion for v and w are 
provided in Koella (1991).  If the mosquito population is considered to be at equilibrium, 






































Appendix B:  Derivation of the basic reproductive number,  0 R 11  















                                                 
11 See Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford 
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We can solve for equilibrium values of 
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The expression for 
* y  is positive if  




































at the steady state point,  ( ) 1,0 E = , which yields 


















For stability, we check that  ( ) det 0 E J < , or equivalently, 





−+ − −< 

. 

















  Resources for the Future  Laxminarayan 
21 
Appendix C: Derivation of  c f  
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Appendix D:  Justification of parameter values (see Table 1 for values and range 
for sensitivity analysis) 
Measured values of the Macdonald's stability index ( µ / 1 ab ) vary between 0.5 for A. 
gambiae in Sudan and 4.9 for A. balabacensis in Southeast Asia, according to Table 14.6 
on page 398 in Anderson and May, which reports values of this index for several regions 
where malaria is endemic.  Our assumed baseline estimate is 6.6 with the index varying 
between 0.42 and 6.9 in the sensitivity analysis.  The specific parameter values are from 
Koella (1991).  
Our baseline level of  0 R  is 100.  This is a close approximate of the  0 R  of 80 
recorded by Molineax and Gramiccia in their work on the Garki Project (Molineaux et al. 
1980).  The force of infection for a susceptible parasite,  w h , is 0.007 per day for baseline 
parameter values.  This falls in the range of empirically estimated values reported by 
Anderson and May in Table 14.7 on page 408 (Anderson and May 1991).  
There are no empirical estimates of  w θ  or  r θ  - hence the parameter values used are 
approximated from those reported in Koella, 1991. Resources for the Future  Laxminarayan 
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Table 1: Parameter values for simulations 
Symbol  Description  Value (range for sensitivity 
analysis) 
a   Biting rate (number of 
bites per female 
mosquito) 
100 per year (50-150) 
1 b   Proportion of infectious 
bites on humans that 
produce an infection 
0.8 (0.4 – 1.1) 
2 b   Proportion of bites by 
susceptible mos-quitoes 
on infected humans that 
produce an infection 
0.8 (0.4 – 1.1) 
0 R   Reproductive number  100 (50-300) 
m   Number of female 
mosquitoes per human 
host 
Calculated based on  0 R  and 
other parameter values. 
µ   Mosquito mortality rate  36 per year (24 – 48) 
w θ   Spontaneous rate of 
recovery of infected 
susceptible individuals 
0.7/year (0.4 – 1) 
r θ   Spontaneous rate of 
recovery of infected 
resistant individuals 
2.4/year (2 – 3) Resources for the Future                                                                                        Laxminarayan   
  24
α   Excess rate of recovery 
of treated individuals 
12/year (9 – 15) 
τ   Incubation period of 
parasites in mosquito 
10 days (8 – 12) 
γ   Rate of loss of immunity  0.1/year (0.08 – 0.12) 
Source: See Appendix D Resources for the Future  Laxminarayan 
25 
Figure 2: Time path of infections, parasite resistance, and cumulative discounted costs 
for different levels of treatment coverage 
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Figure 3 













Discounted Cost of Infection and Treatment under Strategy A
   Base Case









































Discounted Cost of Infection and Treatment under Strategy B
   Base Case
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Figure 5 
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Figure 7 
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